New hope for tough prostate cancer: experimental drug AB-3028 enters human trials

NCT ID NCT07285694

Recruiting now Disease control Sponsor: Arsenal Biosciences, Inc. Source: ClinicalTrials.gov ↗

First seen Jan 04, 2026 · Last updated Apr 25, 2026 · Updated 18 times

Summary

This study tests a new drug, AB-3028, in people with a type of advanced prostate cancer that has stopped responding to standard hormone treatments. About 190 participants will receive the drug to see if it is safe and can shrink tumors or slow the disease. The goal is to find the best dose and understand how well it works.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for METASTATIC CASTRATION-RESISTANT PROSTATE CANCER (MCRPC) are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Contacts and locations

Show contact details

Study contacts

Contact

Phone: •••-•••-•••• Email: •••••@•••••

Locations

City of Hope
RECRUITING

Duarte, California, 91010, United States
Perlmutter Cancer Center - NYU Langone Health
RECRUITING

New York, New York, 10016, United States
USC Norris Comprehensive Cancer Center
RECRUITING

Los Angeles, California, 90033, United States
University of Iowa and Holden Comprehensive Cancer Center
RECRUITING

Iowa City, Iowa, 52242, United States

Conditions

Explore the condition pages connected to this study.

METASTATIC CASTRATION-RESISTANT PROSTATE CANCER (MCRPC)